Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Impax Labs stock surges 4.4% on FDA approval of generic kidney disease medication Renvela
Impax Labs stock surges 4.4% on FDA approval of generic kidney disease medication Renvela
Impax Labs stock surges 4.4% on FDA approval of generic kidney disease medication Renvela
Submitted by
admin
on October 24, 2017 - 9:15am
Source:
Marketwatch
News Tags:
Impax Labs
FDA
kidney disease
generics
Sanofi
Renvela
Headline:
Impax Labs stock surges 4.4% on FDA approval of generic kidney disease medication Renvela
Do Not Allow Advertisers to Use My Personal information
